ghk-cu intramuscular 50mg Copper Peptide Research-Grade GHK-Cu Facial Serum | Empower

Physician-Supervised Peptide Therapy Our clinical approach includes: Full wellness evaluation Personalized treatment recommendations Ongoing follow-up support Secure telehealth care Home delivery available for eligible patients GoalBMI Wellness focuses on physician-supervised wellness care tailored to the patients individual goals. Potential Side Effects & Safety Information Like any wellness or medical treatment, peptide therapy may carry risks and possible side effects depending on the peptide used, dosage, and individual response

No pilling, no greasiness, just a clean canvas

The right vitamin B12 supplement can help bridge the gap, ensuring you're getting enough of this essential B vitamin

CagriSema vs Comparators Feature Receptor targets CagriSema Amylin/calcitonin + GLP-1 Tirzepatide (Zepbound) GIP + GLP-1 Semaglutide alone (Wegovy) GLP-1 Cagrilintide alone Amylin/calcitonin (DACRA) Feature Dosing frequency CagriSema Once weekly Tirzepatide (Zepbound) Once weekly Semaglutide alone (Wegovy) Once weekly Cagrilintide alone Once weekly Feature Maintenance dose CagriSema 2.4 mg + 2.4 mg Tirzepatide (Zepbound) Up to 15 mg Semaglutide alone (Wegovy) 2.4 mg Cagrilintide alone 2.4 mg (in REDEFINE arms) Feature Headline weight loss CagriSema 20.4% at 68 wks (REDEFINE 1, treatment-policy) Tirzepatide (Zepbound) Up to 22.5% at 72 wks (SURMOUNT-1, 15 mg arm) Semaglutide alone (Wegovy) 14.9% at 68 wks (REDEFINE 1 reference arm) Cagrilintide alone 11.5% at 68 wks (REDEFINE 1 reference arm) Feature FDA status (June 2026) CagriSema NDA filed Dec 2025